Evaluating the first drug to show improvement in subtype of autism
Tuesday, April 24, 2012 - 16:20
in Psychology & Sociology
In an important test of one of the first drugs to target core symptoms of autism, researchers are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).